UBS Group
BNR

UBS Group’s Burning Rock Biotech BNR Stock Holding History

UBS Group’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$150K Buy
17,916
+17,508
+4,291% +$248K ﹤0.01% 6963
2026
Q1 		$6.58K Sell
408
-760
-65% -$19.9K ﹤0.01% 8675
2025
Q4 		$23.5K Buy
1,168
+300
+35% +$4.38K ﹤0.01% 7676
2025
Q3 		$7.51K Buy
868
+159
+22% +$1.14K ﹤0.01% 8718
2025
Q2 		$2.24K Buy
709
+599
+545% +$1.86K ﹤0.01% 9496
2025
Q1 		$495 Sell
110
-1,320
-92% -$8.24K ﹤0.01% 9758
2024
Q4 		$9.65K Sell
1,430
-2,815
-66% -$13K ﹤0.01% 8347
2024
Q3 		$13.9K Buy
4,245
+1,665
+65% +$9.18K ﹤0.01% 7564
2024
Q2 		$16.6K Buy
2,580
+2,572
+32,150% +$19.6K ﹤0.01% 7424
2024
Q1 		$60 Buy
+8
New +$67 ﹤0.01% 8904
2023
Q4 		– Sell
-173
Closed -$1.67K – 9329
2023
Q3 		$1.67K Buy
+173
New +$2.7K ﹤0.01% 7858
2023
Q2 		– Sell
-292
Closed -$8.19K – 8949
2023
Q1 		$8.19K Buy
292
+105
+56% +$3.15K ﹤0.01% 7747
2022
Q4 		$4.22K Buy
+187
New +$4.26K ﹤0.01% 9362
2022
Q3 		– Sell
-3,172
Closed -$93K – 10342
2022
Q2 		$93K Buy
3,172
+2,922
+1,169% +$130K ﹤0.01% 5477
2022
Q1 		$23K Buy
250
+114
+84% +$9.9K ﹤0.01% 7281
2021
Q4 		$13K Sell
136
-7,460
-98% -$1.02M ﹤0.01% 8436
2021
Q3 		$1.36M Buy
7,596
+591
+8% +$131K ﹤0.01% 3918
2021
Q2 		$2.06M Buy
+7,005
New +$2.07M ﹤0.01% 3550
2021
Q1 		– Sell
-41
Closed -$9K – 9010
2020
Q4 		$9K Buy
+41
New +$11K ﹤0.01% 7551
2020
Q3 		– Sell
-329
Closed -$89K – 7988
2020
Q2 		$89K Buy
+329
New +$90.2K ﹤0.01% 5388

Other funds holding BNR

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
CL
CRCM LP San Francisco, California $152M AUM 26.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
AIP
Almanack Investment Partners Wayne, Pennsylvania $785M AUM 34.37% 1-Year Est. Return

UBS Group's BNR Position: Q2 2026 in Review

UBS Group increased its Burning Rock Biotech (BNR) stake by 4,291% in Q2 2026, buying an estimated $248K and bringing the position to 17,916 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #6963.

UBS Group first reported a position in BNR in Q2 2020 and has held it in 20 quarters since. The position peaked at $2.06M in Q2 2021. 17 funds tracked by Wall St. Rank hold BNR as of Q2 2026.

  • UBS Group held 17,916 shares of Burning Rock Biotech worth $150K as of Q2 2026.
  • UBS Group bought 17,508 Burning Rock Biotech shares in Q2 2026, an estimated $248K.
  • Burning Rock Biotech made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6963 holding.
  • UBS Group first reported a position in Burning Rock Biotech in Q2 2020 and has held it in 20 quarters since.
  • UBS Group's Burning Rock Biotech position peaked at $2.06M in Q2 2021.
  • 17 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.